

Itch: From the Skin to the Brain – Peripheral and Central Neural **Sensitization in Chronic Itch**

Rami H. Mahmoud BS¹, Omar Mahmoud MD¹, Olusola Oladipo PhD¹, Gil Yosipovitch MD¹



¹Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center, University of Miami Miller School of Medicine

Background

 Itch is an unpleasant sensory phenomenon that is encoded by histaminergic (in acute cases) and nonhistaminergic (in the majority of chronic cases) neuronal pathways

Central Sensitization

Central neural sensitization in itch refers to the

abnormal amplification and dysregulation of itch

signals in the central nervous system (CNS), which includes the brain and spinal cord, resulting in

	r a	\mathbf{b}		CS	

GABAergic Drugs

Increase GABA inhibitory neurotransmission in the CNS and decrease the release of peripheral substance P and calcitonin gene-related peptide from primary afferent neurons by increasing spinal cord GABA.

Chronic itch is often associated with neural

sensitization, which describes the process by which the nervous system experiences heightened sensitivity to stimuli.

• This process of neural sensitization of chronic itch is orchestrated by various signaling pathways and mediators in both the peripheral and central nervous systems.

Objective

To describe the peripheral and central mechanisms

of the neural sensitization of itch and therapeutic

options.

heightened responsiveness and sensitivity to

itch stimuli.

• In the spinal cord, **dysfunction** of **inhibitory** circuits including neuropeptide Y and Bhlhb-5 neurons, as well as attenuation of descending **inhibitory pathways** are at play. • In the brain, neural sensitization is associated structural and functional changes to itchassociated brain areas and networks (i.e., prefrontal area, anterior cingulate cortex).

> Increased neural activity and structural (e) matter volume and density) and function functional connectivity) changes to itch-a regions (e.g., PF, ACC) due to chronic itch


Υ το						
·5	Kappa Opioids	Correct imbalance in endogenous opioid system to help reduce itch sensitization in the CNS.				
ing, d with	Immunomodulatory Therapies (e.g., Dupilumab, Nemolizumab, JAK Inhibitors)	Decrease the effect of itch- promoting cytokines IL-4, IL-13, and IL-31 on peripheral itch- conveying sensory nerve fibers, thereby reducing peripheral sensitization.				
(e.g., changes in gray nal (e.g., altered -associated brain h	NMDA Receptor Targets (e.g., Ketamine)	Inhibit NMDA-dependent excitatory signaling in the periphery (topical application) and centrally (intravenous or inhaled formulations); central-acting formulations may reduce central sensitization by attenuating neural plasticity.				
Brain	Antioxidant Flavonoids	Antioxidant (neutralize free radicals and reactive oxygen species) and anti-inflammatory (decrease pro-inflammatory cytokines and chemokines) effects.				
	Cognitive Behavioral Therapy	Decrease stress, maladaptive thoughts, and scratching behaviors leading to reduced itch and affecting brain structure and function.				
Spinothalamic/ Spinopara-	Transcranial Magnetic Stimulation	Modulate neural activity of brain regions via application of a weak magnetic field through the scalp.				
brachial Tract	Conclusion					
	 Neural sensitization in the context of chronic itch is 					

Peripheral Sensitization

- Peripheral sensitization occurs when a peripheral nerve undergoes increased response to pruritogens or algogens.
- In the skin, **inflammation**, **PAR-2 activation**, and disordered innervation induced by inflammation and scratching represent key mediators of sensitization, stimulating upregulation of itch-related receptors and molecules in the dorsal root ganglia².
- Various itch-related channels and receptors (i.e., Piezo channels, TRP channels, MRGPRs) as well as immune mediators (i.e., skin resident immune cells,

Neural Sensitization

 Inflammation (NGF, PGE2, etc.) Abnormal innervation induced by itching and PAR-2 activation



orchestrated by various signaling pathways and

mediators in both the peripheral and central nervous

neurotrophins, periostin, and phospholipase A2) are

implicated.

• The cycle of itch mediator release from peripheral

nerves, immune cells, and keratinocytes, as well as

the transmission of itch signals, is responsible for the

peripheral sensitization in chronic itch.

 Dysregulation of itch-inhibitory circuits involving Bhlhb5-positive neurons (chemical itch) and NPY-positive neurons (mechanical itch)

Mahmoud O, Oladipo O, Mahmoud RH, Yosipovitch G. Itch: from the skin to the brain - peripheral and central neural sensitization in chronic itch. Front Mol Neurosci. 2023 Oct 2;16:1272230. doi: 10.3389/fnmol.2023.1272230. PMID: 37849619; PMCID: PMC10577434.



Further research is needed to expand our

understanding and therapeutic repertoire.

References

1. Mahmoud, O., Oladipo, O., Mahmoud, R. H., & Yosipovitch, G. (2023). Itch: from the skin to the brain - peripheral and central neural sensitization in chronic itch. Frontiers in molecular neuroscience, 16, 1272230.

2. Yosipovitch G., Rosen J. D., Hashimoto T. (2018). Itch: from mechanism to (novel) therapeutic approaches. J. Allergy Clin. Immunol. 142, 1375-1390.